Bio-Techne, Oxford Nanopore Expand Partnership for Genetics Portfolio Development
The extended agreement through 2032 broadens commercial rights beyond the recently launched carrier screening kit to accelerate diagnostic innovation.
The extended agreement through 2032 broadens commercial rights beyond the recently launched carrier screening kit to accelerate diagnostic innovation.
The deal includes customer accounts and operating assets focused on cancer-related clinical testing services across the United States.
The agency signals intent to withdraw final rule extending regulatory authority to LDTs following federal court ruling that vacated the regulation.
The CLIA-certified facility is now authorized to operate in all 50 states, expanding biomarker testing capabilities nationwide.
The new document provides framework for drug developers on appropriate use and modification of reference AST methods during antimicrobial development.
Lot-to-lot reagent inconsistencies can have significant effects on patient test results.
Cancer diagnostics company adds three clinical advisors and two board members to support commercial growth and platform expansion.
Your lab’s success hinges on a reliable sample management system. But outdated tools may be costing you time, accuracy, and compliance. This guide helps you uncover whether your current system is built for today’s challenges or holding your team back. Take the five-question test, score your solution, and see if it’s time for a smarter approach.